MetaVia IncMTVA
Price$1.54

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$14.4MTTM through 30 Jun 2026
Free Cash Flow -$15.8MTTM through 30 Jun 2026

Margins

Current

Returns

-243.8%ROE
-116.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio1.93x
Net Debt-$10.3Mnet cash position
Cash & Equivalents$12.6M

Quality Metrics

Altman Z-Score-18.74
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Diluted EPS-$2.45TTM
'20'21'22'23'24'25
FY2025: $-7.35

Dividend

No dividend

Capital Allocation

R&D Spend$7.7M

Segment Performance

SegmentRevenueYoYOutlook
Cardiometabolic Pipeline$0
View details

Phase 1 Part 3 titration study data for DA-1726 expected in Q4 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.